Schwab Andrew J. — SEC Form 4 filings
SEC reporting owner CIK 1598549. 28 Form 4 filings on record with FilingPulse; latest filed 2026-09-18.
Transaction summary — filings shown
Covers all 28 filings on record, filed 2024-02-02 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 1,742,423 shares, $19,999,986 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 43 legs across 14 filings — 3,355,634 shares, $29,112,254 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 28.
- Largest priced transaction: sale of 688,358 shares @ $14.90 ($10,256,534) in Enliven Therapeutics, Inc., filed 2024-02-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | 10% owner | 2 | — | 4 legs · 1,325,000 sh · $19,792,500 | — |
| Camp4 Therapeutics Corp (CAMP) | Director | 8 | 1 leg · 909,090 sh · $9,999,990 | 5 legs · 591,875 sh · $2,495,764 | 10 |
| Artiva Biotherapeutics, Inc. (ARTV) | 10% owner | 1 | 1 leg · 833,333 sh · $9,999,996 | — | 5 |
| Entrada Therapeutics, Inc. (TRDA) | 10% owner | 5 | — | 13 legs · 531,285 sh · $4,068,043 | — |
| Skye Bioscience, Inc. (SKYE) | Director, 10% owner | 11 | — | 21 legs · 907,474 sh · $2,755,947 | 7 |
| Latigo Biotherapeutics, Inc. (LTGO) | 10% owner | 1 | — | — | 6 |
Form 4 filings — Schwab Andrew J.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | Skye Bioscience, Inc. (SKYE) | Sale (S): 32,607 @ $1.91 · Sale (S): 1,285 @ $1.91 | EDGAR |
| 2026-08-31 | 4 | Camp4 Therapeutics Corp (CAMP) | Sale (S): 400,000 @ $4.04 | EDGAR |
| 2026-08-26 | 4 | Camp4 Therapeutics Corp (CAMP) | Sale (S): 10 @ $4.50 | EDGAR |
| 2026-08-21 | 4 | Camp4 Therapeutics Corp (CAMP) | Sale (S): 45,147 @ $4.76 · Sale (S): 114,700 @ $4.54 · Sale (S): 32,018 @ $4.50 | EDGAR |
| 2026-08-20 | 4 | Skye Bioscience, Inc. (SKYE) | Sale (S): 45,090 @ $0.38 · Sale (S): 1,830 @ $0.38 · Sale (S): 253,080 @ $0.38 · Sale (S): 10,255 @ $0.35 · Sale (S): 409 @ $0.35 · Sale (S): 57,476 @ $0.35 · +3 more | EDGAR |
| 2026-08-12 | 4 | Latigo Biotherapeutics, Inc. (LTGO) jointly with 5AM Ventures VI, L.P., 5AM Partners VI, LLC, 5AM Opportunities II, L.P., 5AM Opportunities II (GP), LLC, PARMAR KUSH | Conversion (C): 4,975,543 · Conversion (C): 2,350,419 · Conversion (C): 3,152,305 (derivative) @ $0 · Conversion (C): 1,823,238 (derivative) @ $0 · Conversion (C): 866,018 (derivative) @ $0 · Conversion (C): 1,484,401 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, ROCKLAGE SCOTT M | Sale (S): 10,494 @ $7 · Sale (S): 52,317 @ $6.85 | EDGAR |
| 2026-08-05 | 4 | Camp4 Therapeutics Corp (CAMP) | Grant/award (A): 3,179,558 (derivative) @ $1.53 | EDGAR |
| 2026-08-03 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, ROCKLAGE SCOTT M | Sale (S): 114,756 @ $6.93 · Sale (S): 1,718 @ $6.85 | EDGAR |
| 2026-06-12 | 4 | Camp4 Therapeutics Corp (CAMP) | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-11-18 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, ROCKLAGE SCOTT M | Sale (S): 200,000 @ $8.80 | EDGAR |
| 2025-09-15 | 4 | Camp4 Therapeutics Corp (CAMP) | Grant/award (A): 2,941,176 @ $1.53 | EDGAR |
| 2025-08-22 | 4 | Skye Bioscience, Inc. (SKYE) | Sale (S): 58,642 @ $3.57 · Sale (S): 2,314 @ $3.57 · Sale (S): 163,979 @ $3.42 · Sale (S): 6,470 @ $3.42 | EDGAR |
| 2025-07-11 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, ROCKLAGE SCOTT M | Sale (S): 20,065 @ $7.50 · Sale (S): 6,935 @ $7.50 | EDGAR |
| 2025-07-01 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, ROCKLAGE SCOTT M | Sale (S): 55,735 @ $6.91 · Sale (S): 19,265 @ $6.91 · Sale (S): 18,578 @ $6.81 · Sale (S): 6,422 @ $6.81 · Sale (S): 18,578 @ $7.12 · Sale (S): 6,422 @ $7.12 | EDGAR |
| 2025-06-27 | 4 | Camp4 Therapeutics Corp (CAMP) | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2024-10-30 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2024-10-15 | 4 | Camp4 Therapeutics Corp (CAMP) | Conversion (C): 1,337,592 · Conversion (C): 378,463 · Conversion (C): 302,770 · Purchase (P): 909,090 @ $11 · Conversion (C): 15,002,166 (derivative) · Conversion (C): 4,244,770 (derivative) · +1 more | EDGAR |
| 2024-09-13 | 4 | Skye Bioscience, Inc. (SKYE) | Sale (S): 214,556 @ $6.60 · Sale (S): 36,504 @ $6.60 · Sale (S): 1,440 @ $6.60 · Sale (S): 11,758 @ $6.06 · Sale (S): 2,000 @ $6.06 · Sale (S): 79 @ $6.06 | EDGAR |
| 2024-07-24 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P., PARMAR KUSH | Conversion (C): 1,058,284 · Other (J): 112,966 @ $10.20 · Other (J): 348,721 @ $10.20 · Purchase (P): 833,333 @ $12 · Conversion (C): 843,592 (derivative) · Conversion (C): 214,692 (derivative) | EDGAR |
| 2024-03-15 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 450,000 @ $10 | EDGAR |
| 2024-03-04 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., PARMAR KUSH | Sale (S): 688,358 @ $14.90 · Sale (S): 136,642 @ $14.90 | EDGAR |
| 2024-02-02 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 5,206,074 @ $2.31 | EDGAR |
| 2024-02-02 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., PARMAR KUSH | Sale (S): 417,187 @ $15 · Sale (S): 82,813 @ $15 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1598549 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →